The nephrology drugs market would grow at a CAGR of 5.52% over the predicted time frame. The market is expected to increase in value from US$ 15.9 Bn in 2022 to US$ 27.2 Bn in 2032.
The on nephrology drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2577
A recent report provides crucial insights along with application based and forecast information in the Global Nephrology drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Nephrology drugs market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Nephrology drugs market are included as given below:
Nephrology drugs Market Key Players
- AstraZeneca
- AbbVie Inc.
- Akebia Therapeutics, Inc.
- Amgen Inc.
- F. Hoffmann-La Roche
- FibroGen Inc.
- Johnson & Johnson Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Reata Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
Market Segments
By Drug Class
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
By Route of Administration
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Report Objectives
- To define, describe, and forecast the global nephrology drugs market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the nephrology drugs market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nephrology Drugs Market
5.1. COVID-19 Landscape: Nephrology Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nephrology Drugs Market, By Drug Class
8.1. Nephrology Drugs Market, by Drug Class, 2023-2032
8.1.1 ACE Inhibitors
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Angiotensin Receptor Blockers (ARBs)
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. B-Blockers
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Calcium Channel Blockers
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Loop Diuretics
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Erythropoiesis-Stimulating Agents (ESAs)
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Phosphate Binders
8.1.7.1. Market Revenue and Forecast (2020-2032)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Nephrology Drugs Market, By Route of Administration
9.1. Nephrology Drugs Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Intravenous
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Nephrology Drugs Market, By Distribution Channel
10.1. Nephrology Drugs Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Nephrology Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. AstraZeneca
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AbbVie Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Akebia Therapeutics, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amgen Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. F. Hoffmann-La Roche
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. FibroGen Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Johnson & Johnson Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pfizer Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Teva Pharmaceutical Industries Limited
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Reata Pharmaceuticals, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments